Xcout IntelMedicus Pharma Ltd. competitors & alternatives
The 12 closest competitors and alternatives to Medicus Pharma Ltd. among pharmaceuticals companies — ranked by similarity to what Medicus Pharma Ltd. actually does, not by market-cap band.
Subscribe to see Medicus Pharma Ltd.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Medicus Pharma Ltd.
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Medicus Pharma Ltd. at a glance
Medicus Pharma Ltd. is a pharmaceuticals company headquartered in West Conshohocken, Canada. It is publicly listed (MDCX) with a market capitalisation of $11.5M. Xcout tracks 19 named people at Medicus Pharma Ltd., including Raza Bokhari (Chief Executive Officer & Executive Chairman).
Medicus Pharma Ltd. leadership
- Raza BokhariChief Executive Officer & Executive Chairman
- Dr. Raza BokhariExecutive Chairman and CEO
- Carolyn BonnerPresident and Chief Financial Officer
- Andrew Alasdair SmithChief Operating Officer
- Faisal MehmudChief Medical Officer
- Edward J. Brennan Jr.Chief Scientific Officer and Head of R&D Program
13 more named people on record for Medicus Pharma Ltd., with roles, board committees and tenure — see the full roster →
Top 12 Medicus Pharma Ltd. competitors
Ranked by semantic similarity — how close each company is to Medicus Pharma Ltd. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Pharmaceuticals, Biotechnology & Life Sciences
Botanix Pharmaceuticals Ltd. is a dermatology company focused on developing pharmaceutical products and treatments. The company is headquartered in West Perth, Western Australia, and operates within the Australian life sciences market.
Similar pharmaceuticals company
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Biotech, Pharma
Mendus is a pharmaceutical company based in Sweden and the Netherlands that is dedicated to changing the course of cancer treatment by addressing tumor recurrence.
Similar pharmaceuticals company
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Pharmaceuticals, Biotechnology & Life Sciences
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Biotechnology & Pharmaceuticals
Cancer Research Horizons is a specialist drug discovery, development, and commercialisation company that translates lab-bench innovations into diagnostics and treatments for cancer patients. The company collaborates with researchers, partners, and investors to advance oncology therapeutics, manage start-ups, and license research tools and data portfolios.
Similar pharmaceuticals company
Burke Therapeutics, LLC is a pharmaceutical company that markets prescription and over-the-counter products to physicians and pharmacies nationwide. The company also develops early-stage drug candidates specifically designed for patients suffering from dermatological conditions with limited current treatments.
Similar pharmaceuticals company
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
Similar pharmaceuticals company
Biomedica Management Corp is a pharmaceutical company that specializes in the commercialization, distribution, and in-licensing of rare disease and innovative therapies in emerging and underserved markets. It provides biopharmaceutical partners with comprehensive services including market access strategies, regulatory navigation, and reimbursement solutions to expand patient access to breakthrough treatments.
Similar pharmaceuticals company
Marlinz Pharma develops and markets science-backed, clinical nail and skin care products, specializing in treatments for fungal and non-fungal conditions. The company distributes its product line, including antifungals, foot soaks, and therapeutic creams, primarily through healthcare providers.
Similar pharmaceuticals company
Established in 1987 and headquartered in Huddinge, Sweden, Medivir AB (publ) is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products. Its primary therapeutic area is oncology, with operations extending across Sweden and internationally. The company's marketed product, Zoviduo (also known as Xerclear), treats labial herpes. Medivir's robust pipeline features several investigational compounds: Remetinostat for MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818 for liver cancer; MIV-711 for osteoarthritis; and Birinapant along with IGM-8444, both targeting solid tumors. Furthermore, Medivir engages in strategic collaborations, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS-CoV-2, and has licensing agreements with Tango Therapeutics and Ubiquigent Limited for preclinical research programs, specifically Ubiquigent's USP7 program.
Similar pharmaceuticals company
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Medicus Pharma Ltd. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Medicus Pharma Ltd.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →